Close Menu

NEW YORK (GenomeWeb) – Luminex reported after the close of the market on Monday that its second quarter revenues rose 19 percent, driven in part by automated sample-to-answer molecular products sales, which rose 44 percent over the prior-year quarter to $10.7 million from $7.4 million.

For the three months ended June 30, the firm reported total revenues of $76.5 million, up from $64.2 million a year ago, and beating the consensus Wall Street estimate of $75.5 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.

The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.

The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.

In Science this week: ANXA11 variants affect calcium homeostasis and stress granule disassembly in ALS, and more.